EMEA-000410-PIP01-08-M06 - paediatric investigation plan

Regadenoson

Key facts

• Invented name:
  Rapiscan
• Active Substance:
  Regadenoson
• Therapeutic area:
  Surgical and medical procedures
• Decision number:
  P/0029/2024
• PIP number:
  EMEA-000410-PIP01-08-M06
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Diagnosis of myocardial perfusion disturbances
• Route(s) of administration:
  Intravenous use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  29/01/2024

Decision

P/0029/2024 : EMA decision of 29 January 2024 on the acceptance of a modification of an agreed paediatric investigation plan for regadenoson (Rapiscan), (EMEA-000410-PIP01-08-M06)

AdoptedReference Number: EMA/29055/2024